News
The Houston-based Empower Pharmacy is seeking to dismiss a lawsuit that targets its ability to sell popular diabetes and ...
Eli Lilly ( LLY 0.36%) has been a great growth pick for investors over the past few years. The pharma company, thanks to its ...
Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Both ...
Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...
LLY breaks above its 50-day average as Mounjaro and Zepbound drive revenues. Is this a new entry point for investors?
A 28-year-old man who started using the injectable medication on Saturday (7 June) has opened up on his experience so far ...
Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...
Eli Lilly’s diabetes and obesity management drug Mounjaro saw a sharp rise in sales for the third consecutive month, driven ...
Eli Lilly & Co. increased sales of weight-loss and diabetes drug Mounjaro 60% in India in May from April in its second full ...
Eli Lilly's weight-loss and diabetes drug Mounjaro, has seen sales in India jump 60 per cent between April and May. The ...
5d
24/7 Wall St. on MSNVisa, Eli Lilly or Netflix— Which Stock Will Be A Trillion Dollar Company Next?Companies are always in the race for the top spot, and the only way to achieve it is by reaching a high market valuation. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results